Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047950 | 0.99 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL891534 | 0.99 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 | |
| Lindane SCHEMBL8049713 | 0.94 | CDK1 (0.51) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL9619715 | 0.88 | CDK1 (0.56) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL3191785 | 0.87 | CDK1 (0.51) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL3655532 | 0.87 | CDK1 (0.51) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL9241365 | 0.87 | CDK1 (0.53) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL1614945 | 0.87 | LDHA (0.44) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL18167468 | 0.86 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL10390144 | 0.86 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401307-A1 | METHODS OF PREPARING RENEWABLE BUTADIENE AND RENEWABLE ISOPRENE | GEVO, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099201-A1 | METHODS OF PREPARING RENEWABLE BUTADIENE AND RENEWABLE ISOPRENE | GEVO, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216958-A1 | Methods of Preparing Renewable Butadiene and Renewable Isoprene | AGRI-ENERGY, LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216958-A1 | Methods of Preparing Renewable Butadiene and Renewable Isoprene | ADH1A, ADH1C, FASN | CDK1 2851/4885CCNB1 761/4885LDHA 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.